Puyan, a subsidiary of Pusheng (4117), entrusted the National Institute of Health to cooperate with “Candida auris” to obtain the experimental results with a bacteriostatic rate of 99.7%
With the post-epidemic changes in medication and living habits, including normal epidemic viruses, bacterial infections and new coronary pneumonia, etc.The increase in the proportion of antibiotics used by virus-infected patients has led to a simultaneous increase in the proportion of drug-resistant bacteria, which is also an issue of international public health attentionespecially the US Centers for Disease Control and Prevention (CDC) has recently warned that the highly drug-resistant, deadly Candida auris (Candida auris) has cases in half of the states in the US, and nearly one-third of patients are infected Passed away within 90 days after the death. Judging from the 2,377 clinical cases and 5,754 screening medical records in 2022, an increase of 61% and 42% respectively compared with 2021, it can be seen that Candida auris is spreading at an alarming rate. The US CDC Candida auris is also considered an “urgent public threat”.
Pusheng Co., Ltd. (hereinafter referred to as “Pusheng”, stock code: 4117), a major precision medicine manufacturer, focuses onAntimicrobial peptide drug (AMP) development, and health care and medical beauty product manufacturersPuyan Biotechnology, a subsidiary of the transformation, has achieved good results in recent business development.oh care OakvilleThe self-owned brand P113+ antibacterial health care and medical beauty product series, in the first half of this year, launched new products such as antibacterial paper towels, antibacterial sanitary napkins, children’s electric toothbrushes, oral cleaning sticks and oral spray medical equipment, and continued to increase sales in Taiwan, China, and Malaysia. In addition to the performance, not only that, as countries have gradually increased their attention to the “super bacteria” with multi-drug resistance, they have also entrusted the National Institute of Health to cooperate with P113 antibacterial peptides have been carried out related antibacterial experiments against “Candida auris”. The results of the current experiments show that P113 antibacterial peptides have a bacteriostatic rate of 99.7% higher than that of Candida aurishas the opportunity to become the asset of Puyan’s next new drug development.
Pusheng further stated that the P113 antibacterial peptide drug was first discovered by the Boston University School of Dentistry in the United States. The antibacterial protein component “12 amino acid” (12 amino acid) obtained from the extraction of oral saliva has a specific antibacterial mechanism. It can inhibit bad bacteria and retain good bacteria to maintain the balance of bacteria species. Not only has no allergic reaction, high skin affinity, and no drug resistance, it can widely inhibit the growth of more than 40 kinds of fungi and bacteria (such as Candida albicans, Candida auris, large intestine bacilli, drug-resistant Staphylococcus aureus, etc.), currentlyIt has passed the US FDA new drug clinical phase II (Phase IIb) experiment, and in 294 subjects, the data results show that the P113 antibacterial peptide drug has three anti-plaque, anti-gingivitis and anti-bleeding gums., two times a day, after four weeks of continuous use, the test group has improved, and for the clinical trial of oral candidiasis (also known as oral thrush), for HIV-positive subjects with oral candidiasis infection, use it four times a day , Continuous use for 14 days has obvious therapeutic effect.Puyan subsidiary alsoThe evaluation plan starts the Phase III clinical trial of the P113 antibacterial peptide drug in the US FDA to advance the company to the next operating milestone.
Looking forward to future operations, Pusheng adheres to the concept of protecting the health of the whole people, and improves its five core business areas, including precision testing, liquid biopsy, CDMO (commissioned development and production), testing services, and P113 antibacterial peptide drugs. On the one hand, the subsidiary Puyansheng ohcare Oakwell’s self-owned brand, which is a subsidiary of the technology, has been fermented at the end of 2022 and has gradually increased its order placement through new products, expansion of sales channel layout, and continuous deepening of cooperation with Christina Group on antimicrobial protein application-related products. , strive to deepen its precision testing service business, expand global business orders for products including cervical cancer, HIV, hepatitis C and other testing reagents, new crown pneumonia and flu rapid screening, and actively expand the flagship AIO (All in One )’s new fully automated nucleic acid detection equipment, CellBio™ Circulating Tumor Cell (CTC) Detection System products and other self-owned equipment sales business, etc. Among them, CellBio™ Circulating Tumor Cell (CTC) Detection System products also continue to cooperate with Fubon Life Insurance to expand Taiwan The business opportunities of cancer screening are all expected to create a positive effect on Pusheng’s future operations.
